|
1
|
Kudo M: Hepatocellular carcinoma in 2011
and beyond: from the pathogenesis to molecular targeted therapy.
Oncology. 81(Suppl 1): 1–10. 2011. View Article : Google Scholar
|
|
2
|
Meguro M, Mizuguchi T, Kawamoto M and
Hirata K: The molecular pathogenesis and clinical implications of
hepatocellular carcinoma. Int J Hepatol. 2011:8186722011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamazaki K, Masugi Y and Sakamoto M:
Molecular pathogenesis of hepatocellular carcinoma: altering
transforming growth factor-β signaling in hepatocarcinogenesis. Dig
Dis. 29:284–288. 2011. View Article : Google Scholar
|
|
4
|
Rong M, Chen G and Dang Y: Increased
miR-221 expression in hepatocellular carcinoma tissues and its role
in enhancing cell growth and inhibiting apoptosis in vitro. BMC
Cancer. 13:212013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zou C, Li Y, Cao Y, Zhang J, Jiang J,
Sheng Y, Wang S, Huang A and Tang H: Up-regulated MicroRNA-181a
induces carcinogenesis in Hepatitis B virus-related hepatocellular
carcinoma by targeting E2F5. BMC Cancer. 14:972014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG and
Qin CK: Upregulation of microRNA-25 associates with prognosis in
hepatocellular carcinoma. Diagn Pathol. 9:472014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Yao J, Shi X, Hu L, Li Z, Song T
and Huang C: MicroRNA-302b suppresses cell proliferation by
targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells.
BMC Cancer. 13:4482013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aravalli RN, Steer CJ and Cressman EN:
Molecular mechanisms of hepatocellular carcinoma. Hepatology.
48:2047–2063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thorgeirsson SS, Lee JS and Grisham JW:
Functional genomics of hepatocellular carcinoma. Hepatology. 43(2
Suppl 1): S145–S150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Villanueva A, Newell P, Chiang DY,
Friedman SL and Llovet JM: Genomics and signaling pathways in
hepatocellular carcinoma. Semin Liver Dis. 27:55–76. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roessler S, Budhu A and Wang XW:
Deciphering cancer heterogeneity: the biological space. Front Cell
Dev Biol. 2:122014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shirasaki T, Honda M, Shimakami T, Horii
R, Yamashita T, Sakai Y, Sakai A, Okada H, Watanabe R, Murakami S,
et al: MicroRNA-27a regulates lipid metabolism and inhibits
hepatitis C virus replication in human hepatoma cells. J Virol.
87:5270–5286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar :
|
|
15
|
Wu D, Ding J, Wang L, Pan H, Zhou Z, Zhou
J and Qu P: microRNA-125b inhibits cell migration and invasion by
targeting matrix metallopeptidase 13 in bladder cancer. Oncol Lett.
5:829–834. 2013.PubMed/NCBI
|
|
16
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghildiyal M and Zamore PD: Small silencing
RNAs: an expanding universe. Nat Rev Genet. 10:94–108. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takahashi RU, Makiko O and Ochiya T: Role
of microRNA in cancer development: biology and clinical
applications. Nihon Geka Gakkai Zasshi. 113:197–203. 2012.(In
Japanese). PubMed/NCBI
|
|
21
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ura S, Honda M, Yamashita T, Ueda T,
Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K and Kaneko
S: Differential microRNA expression between hepatitis B and
hepatitis C leading disease progression to hepatocellular
carcinoma. Hepatology. 49:1098–1112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ventura A and Jacks T: MicroRNAs and
cancer: short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu D, Zhou Y, Pan H, Zhou J, Fan J and Qu
P: microRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014.PubMed/NCBI
|
|
25
|
Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou
J: MicroRNA-133 inhibits cell proliferation, migration and invasion
by targeting epidermal growth factor receptor and its downstream
effector proteins in bladder cancer. Scand J Urol. 47:423–432.
2013. View Article : Google Scholar
|
|
26
|
Kawakami K, Enokida H, Chiyomaru T,
Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama
K, Nohata N, et al: The functional significance of miR-1 and
miR-133a in renal cell carcinoma. Eur J Cancer. 48:827–836. 2012.
View Article : Google Scholar
|
|
27
|
Kano M, Seki N, Kikkawa N, Fujimura L,
Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and
Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive
miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J
Cancer. 127:2804–2814. 2010. View Article : Google Scholar
|
|
28
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ruebel K, Leontovich AA, Stilling GA,
Zhang S, Righi A, Jin L and Lloyd RV: MicroRNA expression in ileal
carcinoid tumors: downregulation of microRNA-133a with tumor
progression. Mod Pathol. 23:367–375. 2010. View Article : Google Scholar :
|
|
30
|
Rao PK, Missiaglia E, Shields L, Hyde G,
Yuan B, Shepherd CJ, Shipley J and Lodish HF: Distinct roles for
miR-1 and miR-133a in the proliferation and differentiation of
rhabdomyosarcoma cells. FASEB J. 24:3427–3437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chomczynski P and Sacchi N: The
single-step method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction: twenty-something years
on. Nature Protoc. 1:581–585. 2006. View Article : Google Scholar
|
|
32
|
Tao J, Lu Q, Wu D, Li P, Xu B, Qing W,
Wang M, Zhang Z and Zhang W: microRNA-21 modulates cell
proliferation and sensitivity to doxorubicin in bladder cancer
cells. Oncol Rep. 25:1721–1729. 2011.PubMed/NCBI
|
|
33
|
Dong DL, Chen C, Huo R, Wang N, Li Z, Tu
YJ, Hu JT, Chu X, Huang W and Yang BF: Reciprocal repression
between microRNA-133 and calcineurin regulates cardiac hypertrophy:
a novel mechanism for progressive cardiac hypertrophy.
Hypertension. 55:946–952. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: microRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
|
35
|
Rao PK, Kumar RM, Farkhondeh M,
Baskerville S and Lodish HF: Myogenic factors that regulate
expression of muscle-specific microRNAs. Proc Nat Acad Sci USA.
103:8721–8726. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bostjancic E, Zidar N, Stajer D and Glavac
D: MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated
in human myocardial infarction. Cardiology. 115:163–169. 2010.
View Article : Google Scholar
|
|
37
|
Uchida Y, Chiyomaru T, Enokida H, Kawakami
K, Tatarano S, Kawahara K, Nishiyama K, Seki N and Nakagawa M:
MiR-133a induces apoptosis through direct regulation of GSTP1 in
bladder cancer cell lines. Urol Oncol. 31:115–123. 2013. View Article : Google Scholar
|
|
38
|
Chiyomaru T, Enokida H, Kawakami K,
Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa
M: Functional role of LASP1 in cell viability and its regulation by
microRNAs in bladder cancer. Urol Oncol. 30:434–443. 2012.
View Article : Google Scholar
|
|
39
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
40
|
Han X, Yan DM, Zhao XF, Matsuura H, Ding
WG, Li P, Jiang S, Du BR, Du PG and Zhu X: GHGKHKNK octapeptide
(P-5m) inhibits metastasis of HCCLM3 cell lines via regulation of
MMP-2 expression in in vitro and in vivo studies. Molecules.
17:1357–1372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lou L, Chen YX, Jin L, Li X, Tao X, Zhu J,
Chen X, Wu S, Ye W, He J, et al: Enhancement of invasion of
hepatocellular carcinoma cells through lysophosphatidic acid
receptor. J Int Med Res. 41:55–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun MH, Han XC, Jia MK, Jiang WD, Wang M,
Zhang H, Han G and Jiang Y: Expressions of inducible nitric oxide
synthase and matrix metalloproteinase-9 and their effects on
angiogenesis and progression of hepatocellular carcinoma. W J
Gastroenterol. 11:5931–5937. 2005.
|
|
43
|
Verma S, Kesh K, Ganguly N, Jana S and
Swarnakar S: Matrix metalloproteinases and gastrointestinal
cancers: Impacts of dietary antioxidants. World J Biol Chem.
5:355–376. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kallakury BV, Karikehalli S, Haholu A,
Sheehan CE, Azumi N and Ross JS: Increased expression of matrix
metalloproteinases 2 and 9 and tissue inhibitors of
metalloproteinases 1 and 2 correlate with poor prognostic variables
in renal cell carcinoma. Clin Cancer Res. 7:3113–3119.
2001.PubMed/NCBI
|
|
45
|
Morgia G, Falsaperla M, Malaponte G,
Madonia M, Indelicato M, Travali S and Mazzarino MC: Matrix
metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2,
MMP-9) markers of prostate cancer. Urol Res. 33:44–50. 2005.
View Article : Google Scholar
|
|
46
|
Gao ZH, Tretiakova MS, Liu WH, Gong C,
Farris PD and Hart J: Association of E-cadherin, matrix
metalloproteinases, and tissue inhibitors of metalloproteinases
with the progression and metastasis of hepatocellular carcinoma.
Mod Pathol. 19:533–540. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jang JW, Park ST, Kwon JH, You CR, Choi
JY, Jung CK, Bae SH and Yoon SK: Suppression of hepatic tumor
growth and metastasis by metronomic therapy in a rat model of
hepatocellular carcinoma. Exp Mol Med. 43:305–312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zeng HY
and Gao DM: Gene expression profiling of fixed tissues identified
hypoxia-inducible factor-1alpha, VEGF, and matrix
metalloproteinase-2 as biomarkers of lymph node metastasis in
hepatocellular carcinoma. Clin Cancer Res. 17:5463–5472. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen R, Cui J, Xu C, Xue T, Guo K, Gao D,
Liu Y, Ye S and Ren Z: The significance of MMP-9 over MMP-2 in HCC
invasiveness and recurrence of hepatocellular carcinoma after
curative resection. Ann Surg Oncol. 19(Suppl 3): S375–S384. 2012.
View Article : Google Scholar
|
|
50
|
Hong S, Park KK, Magae J, Ando K, Lee TS,
Kwon TK, Kwak JY, Kim CH and Chang YC: Ascochlorin inhibits matrix
metalloproteinase-9 expression by suppressing activator
protein-1-mediated gene expression through the ERK1/2 signaling
pathway: inhibitory effects of ascochlorin on the invasion of renal
carcinoma cells. J Biol Chem. 280:25202–25209. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Santhekadur PK, Gredler R, Chen D, Siddiq
A, Shen XN, Das SK, Emdad L, Fisher PB and Sarkar D: Late SV40
factor (LSF) enhances angiogenesis by transcriptionally
up-regulating matrix metalloproteinase-9 (MMP-9). J Biol Chem.
287:3425–3432. 2012. View Article : Google Scholar :
|
|
52
|
Jiang YF, Yang ZH and Hu JQ: Recurrence or
metastasis of HCC: predictors, early detection and experimental
antiangiogenic therapy. World J Gastroenterol. 6:61–65. 2000.
|
|
53
|
Hayasaka A, Suzuki N, Fujimoto N, Iwama S,
Fukuyama E, Kanda Y and Saisho H: Elevated plasma levels of matrix
metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in
hepatocellular carcinoma. Hepatology. 24:1058–1062. 1996.
View Article : Google Scholar : PubMed/NCBI
|
